Hyperbaric Oxygen Therapy at Extivita
Hyperbaric Oxygen Therapy, also known as HBOT involves breathing 100% oxygen in a pressurized chamber to increase oxygen levels in blood plasma. A century of clinical research has shown that increased oxygen in plasma accelerates our natural ability to heal through neurogenesis and angiogenesis. In addition, HBOT upregulates over 8000 anti-inflammatory genes and activates the release of stem cells and growth factors associated with the body’s regenerative and reparative processes.
Globally, HBOT is used to extend and improve quality of life by augmenting the treatment of all injuries, diseases, and infections as well as to improve overall wellness and the physical performance of athletes.
Unique treatment plans created for patients suffering from a variety of conditions
Used in hospitals and clinics around the world
Reduce inflammation and enhance the body’s natural ability to heal
EXPLORING HBOT RESEARCH
Globally, Hyperbaric Oxygen Therapy is used to extend and improve quality of life for patients by augmenting the treatment of all injuries, diseases, and infections as well as to improve overall wellness and the physical performance of athletes. Explore our research database to see if HBOT might be right for you!
Recent HBOT Research
Retrospective Case Series of Traumatic Brain Injury and Post-Traumatic Stress Disorder Treated with Hyperbaric Oxygen Therapy
Returning veterans are frequently diagnosed with traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD). Considering a recent case-controlled study of hyperbaric oxygen therapy (HBOT) reporting a reduction in suicidal ideation, we investigated retrospectively three veterans with chronic TBI/PTSD symptoms who were treated with multiple rounds of HBOT with neurophysiological testing performed before and after treatment. Improvements were detected on parameters within neurocognitive domains, including reductions in suicide-related symptoms. These findings independently confirm that HBOT may be effective in treating specific symptoms of TBI/PTSD that are not currently addressed with existing therapeutic approaches.
Hyperbaric oxygen therapy (HBOT) is defined as the use of oxygen at higher than atmospheric pressure for the treatment of underlying disease processes and the diseases they produce. Modern HBOT in which 100% O2 is breathed in a pressurized chamber dates back to the 1930s, when it was first used for treatment of decompression illness in divers. There are currently 13 FDA-approved uses for HBOT, including decompression illness, gas gangrene, air embolism, osteomyelitis, radiation necrosis, and the most recent addition—diabetic ulcers. HBOT can dramatically and permanently improve symptoms of chronic TBI months or even many years after the original head injury. This assertion is generally met with skepticism within the medical establishment because we have been taught for generations that any post-concussion symptoms persisting more than 6 months or so after a head injury are due to permanent brain damage that cannot be repaired.
The National Brain Injury Rescue and Rehabilitation Study – a multicenter observational study of hyperbaric oxygen for mild traumatic brain injury with post-concussive symptoms
The National Brain Injury Rescue and Rehabilitation Project was established as a preliminary study to test the safety and practicality of multi-center hyperbaric oxygen administration for the post-concussive symptoms of chronic mild traumatic brain injury as a precursor to a pivotal, independent, multi-center, controlled clinical trial. This report presents the results for 32 subjects who completed a preliminary trial of hyperbaric oxygen several years before the passage of the 21 st Century Cures Act. This study anticipated the Act and its reassessment of clinical research. Subjects received 40-82 one-hour treatments at 1.5 atmospheres absolute 100% oxygen. Outcome measures included repeated self-assessment measures and automated neurocognitive tests. The subjects demonstrated improvement in 21 of 25 neurocognitive test measures observed. The objective neurocognitive test components showed improvement in 13 of 17 measures. Earlier administration of hyperbaric oxygen post injury, younger age at the time of injury and hyperbaric oxygen administration, military status, and increased number of hyperbaric oxygen administrations were characteristics associated with improved outcomes. There were no adverse events. Hyperbaric oxygen was found to be safe, inexpensive and worthy of clinical application in the 21 st Century model of facile data collection provided by recent research regulatory shifts in medicine. The study was approved by the ethics review committee of the Western Institutional Review Board (WIRB; Protocol #20090761).
Noninvasive Therapy that can help in a variety of medical conditions
Noninvasive Therapy that can help in a variety of medical conditions
Benefits of Hyperbaric Oxygen Therapy
Maximizes Oxygen Transport
Preserves, Repairs, & Enhances Cellular Functions
Increases Amount of Oxygen in the Blood
Accelerates Wound Healing
Prevents Further Cellular Damage
Reduces Inflammation & Swelling
Enhances Anti-Microbial Function
ABOUT OUR CLINIC
WE ARE MULTI-SEAT HYPERBARIC CHAMBER CLINIC
A multi-seat hyperbaric chamber is designed to treat multiple patients at a time. Patients sit in chairs while they receive oxygen through individual hoods while the chamber pressurizes to equivalent pressure of a shallow dive.
Recent HBOT News
Many Oklahomans suffer from debilitating conditions resulting from head trauma. Brain injuries may result from active duty military service, sports activities, automobile accidents, and from a host of other traumatic events. State Rep. Jay Steagall (R-Yukon), chair of...
Oxygen in the hyperbaric chamber provides relief after radiotherapy, new research has found. Radiotherapy is part of many treatment protocols of cancer in organs such as the prostate, cervix, ovaries, and colon and it may cause several side-effects linked to damage of...
The AC133 antigen is a novel antigen selectively expressed on a subset of CD34+ cells in human fetal liver, bone marrow, and blood as demonstrated by flow cytometric analyses. In this study, we have further assessed the expression of AC133 on CD34+ cells in hemopoietic samples and found that there was a highly significant difference between normal bone marrow and cord blood versus aphereses (p <0.0001) but not between bone marrow and cord blood. Most of the clonogenic cells (67%) were contained in the CD34+AC133+ fraction. Compared with cultures of the CD34+AC133- cells, generation of progenitor cells in long-term culture on bone marrow stroma was consistently 10- to 100-fold higher in cultures initiated with CD34+AC133+ cells and was maintained for the 8-10 weeks of culture.